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tion. Methods: IMS Disease Analyzer™ (DA) database was used, focusing on 
patients with or without diabetes in general practice in France. The analysis was 
performed retrospectively from 2001 to 2013. The Hazard Ratios (HR; Cox regres-
sion) for the risk of cancer in diabetic versus non-diabetic patients were adjusted 
for demographic and clinical variables. IMS Oncology Analyzer™ (OA) database was 
also used to describe the cancer patient profile in 2013. Results: Overall 3.1% of 
patients in DA are diabetic. 75,104 patients were diagnosed with type-2 Diabetes 
Mellitus (T2DM). This population was matched to a control group in terms of age 
(60±15 years) and gender (male: 52%). The overall risk of cancer was lower in T2DM 
patients than in patients without diabetes (HR: 0.81; CI: 0.76 to 0.85). Those patients 
were less likely to develop breast, prostate, lung cancer or non-hodgkin lymphoma. 
Nevertheless, their risk was significantly higher regarding liver cancer (HR: 1.99; CI: 
1.46 to 2.72), pancreatic cancer (HR: 2.13; CI: 1.51 to 3.00) and endometrial cancer 
(HR: 1.25; CI: 1.01 to 1.55). No significant increase in risk was observed in colorectal, 
stomach, kidney, thyroid, urinary bladder, gall bladder and oesophageal cancer. 
OA showed a higher proportion of diabetic patients among the cancer population 
(14.6%, n= 10,621). Consistently, this rate was even higher in patients diagnosed 
with pancreatic (28.7%, n= 362), liver (27.0%, n= 256) and endometrial cancer (21.7%, 
n= 161). ConClusions: This retrospective analysis showed that T2DM may increase 
the risk of certain cancer types but seems to prevent from some others. Further 
research is required to evaluate the factors involving the diabetes-cancer correla-
tions, such as the anti-diabetic drugs.
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objeCtives: To forecast the number of advanced melanoma (AM) patients (Stage 
III unresectable and Stage IV) newly initiating treatment over 5 years (2014-2018) 
by line of therapy and clinical/tumor characteristics including BRAF/PD-L1 muta-
tions status and rate of brain metastases. Methods: A patient count model was 
developed to forecast the AM population using historical rate data (1991-2012) and 
other population parameters including incidence rate annual percent change, stage 
at diagnosis, rates of disease progression and survival obtained through a compre-
hensive literature review and hand-search of cancer registry websites. Analysis of a 
cross-sectional sample (Ipsos Global Oncology Monitor) of 1,297 patients in the EU-5 
was used to address any clinical data gaps. The model was validated by compar-
ing projected 5-year prevalence rates to GLOBOCAN 2012 estimates. Results: The 
model-projected number (rounded to nearest 100) of incident melanoma cases for 
2014 was: Germany= 23,100; UK= 18,900; France= 12,400; Italy= 12,000; Spain= 5,800. 
Of incident cases, 11.3%-13.0% were treatment eligible AM. Incidence rates increases 
of 1.7-7.8% per year were applied based on historical trends. Analysis of IPSOS data 
and review of the literature showed BRAF and PD-L1 prevalence rates of 45.4%-56.2% 
and 15.9%-16.7%, in AM patients, respectively. Literature-derived, brain metastasis 
prevalence ranged from 15.9-36.0% in Stage IV patients. Considering case progres-
sion, resection and adjuvant treatment rates, the forecasted number of AM patients 
eligible for 1stand 2nd line treatment in 2018 is, respectively: Germany= 3,700 and 
1,700; UK= 3,100 and 1,400 France= 1,900 and 500; Italy= 1,800 and 1,000; Spain= 1,100 
and 400, representing approximately 10.8-12.0% of incident cases. ConClusions: 
While melanoma incidence is projected to increase over the next 5 years the 
majority of incident cases will be diagnosed in earlier disease stages. Under these 
assumptions, the largest proportion of the incident melanoma population that is 
AM patients initiating treatment is expected to be 12% in 2018, a slight decline 
from 13% in 2014.
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objeCtives: The objective of this study is to develop and validate a conditional 
logistic regression model for the prediction of locoregional recurrence (LRR) of 
breast cancer. To make a translation to clinical practice a web based nomogram 
was made. Methods: Women first diagnosed with early breast cancer (without 
distant metastasis or ingrowth in the chest wall or skin) between 2003-2006 were 
selected from the Netherlands Cancer Registry (n= 39,929). Risk factors for LRRs 
within five year of the primary treatment were determined using logistic regres-
sion. Risks were determined per year, conditional on not being diagnosed with 
recurrence in the previous year. The presence of interaction and collinearity in 
the nomogram was assessed, as well as the discrimination by means of the area 
under the ROC curve and calibration by the Hosmer-Lemeshow goodness-of-fit test 
in deciles. Data on primary tumours diagnosed between 2007-2008 from a selec-
tion of Dutch hospitals was used for external validation of the performance of 
the nomogram (n= 13,792). Results: The final model included the variables grade, 
size, multifocality, and nodal involvement of the primary tumour, type of surgery, 
and whether patients were treated with radio-, chemo- or hormone therapy. The 
modelling group showed an area under the ROC curve of 0.82,0. 74,0. 67,0. 70 and 
0.60 respectively per subsequent year after primary treatment. The calibration was 
sufficient. All effects in the validation group were in the same direction, and the 
estimates in the validation group did not differ significantly from the modelling 
group. ConClusions: This validated nomogram can be used as an instrument to 
aid clinical decision-making and to identify patients with a high risk of breast cancer 
recurrence who might benefit from a more intensive follow-up after breast cancer.
using electronic hospital records. Survival was assessed using the Kaplan-Meier 
estimator. Recurrence patterns were investigated by type of first recurrence and 
time-to-recurrence. A multivariate cox regression was used to analyze whether 
time-to-recurrence was associated with gender, age and tumor thickness. Emigrated 
patients (n= 10) and patients with an unknown recurrence status (n= 144) were 
excluded. Results: Of all 817 patients, 111 patients (13.6%) experienced disease 
progression (median follow-up: 5.5 years). Patients who developed a recurrence had 
a lower survival compared to patients who did not developed a recurrence (median 
OS: 9.4 years versus median has not yet been reached; 5-year survival rate: 69.9% 
versus 96.6%; p< 0.001). The most frequent type of first recurrence was lymphatic 
(36.9%), followed by distant (22.5%), local (21.6%) and intralymphatic (9.9%), respec-
tively. The median time-to-recurrence has not yet been reached; however, in case of 
a recurrence, the median time-to-recurrence was 2.5 years (minimum: 0.01 years; 
maximum: 9.8 years). The time-to-recurrence was not statistically significantly asso-
ciated with gender (HR= 0.81; p= 0.29), age (HR= 1.01; p= 0.38) and tumor thickness 
(HR= 1.03; p= 0.76). ConClusions: Long-term surveillance of stage IB melanomas 
is of utmost importance, because survival subsequent to recurrence is much lower 
than expected. The risk of developing a recurrence was substantial; however, the 
time-to-recurrence was not associated with gender, age and tumor thickness.
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objeCtives: The objective of this study was to evaluate both the incidence 
of metastatic Castrate Resistant Prostate Cancer (mCRPC) and the number of 
mCRPC patients who receive specific mCRPC treatments (mCRPCTT): chemo-
therapy and second generation Hormone Therapies (ADT manipulations were 
not included). Methods: This study was conducted in 8 European countries and 
Australia The incidence of mCRPC patients was assessed using several sources: 
national cancer registries, a literature review and an ad-hoc chart review where 
292 oncologists, 76 onco-radiotherapists and 357 urologists reported information 
about 4171 prostate cancer patients. Of these, 2401 had metastatic castrate resistant 
disease. Patient characteristics and treatments received were assessed and reported 
separately by country. Results: Across all 9 countries, 76 200 new patients were 
diagnosed mCRPC over the past year. Of these patients, 35% (26 400 patients) went 
to supportive care without receiving any mCRPC TT while 65% (49 800 patients) 
received a 1L mCRPCTT. Prior to receiving any 1L mCRPCTT, 43% of patients had ADT 
manipulations during a short transitional period (median duration = 1 month). Of 
the 49 800 patients who received a 1L mCRPCTT, 59% (29 250) went to a 2L mCRPCTT, 
15% deceased during or just after the 1L TT and 26% went on to receive supportive 
care only. Of the 29 250 patients who received a 2L mCRPCTT, 46% (13 500) went to 
a 3L mCRPCTT. ConClusions: Our methodology enabled us to assess incidence 
figures and the volume of mCRPC patients who receive specific mCRPCTT: over 
one-third of mCRPC patients did not receive any mCRPCTT. Among the 65% who 
received a 1L TT, 59% receive a 2L mCRPCTT.
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objeCtives: Explore differences/similarities in epidemiology and drug treatment 
of metastatic breast cancer (MBC) in EU5. Methods: All data was derived from the 
Kantar Health CancerMPact database, sources for which include country specific 
cancer registries, published scientific studies and proprietary physician surveys 
comprising 85 doctors seeing 9,255 patients per month. Age and gender specific 
incidence rates, annual stage specific progression rates and annual stage specific 
survival rates are used to calculate total number of surviving patients at a specific 
stage up to 10 years after diagnosis. Results: Prevalence of BC ranged between 
41-73 per 100K population across EU-5. Among BC patients, prevalence of MBC was 
similar: 8% (UK, Italy) to 10% (Germany, France, Spain). Overall 62% of MBC patients 
were diagnosed with HER2-negative disease (56% Germany-70% France). Among 
these patients 35-40% had active disease and were treated with chemotherapy. 
Patients with triple negative disease had had fewer lines of treatment than did 
not triple negative. Patients who are HER2-negative generally receive between two 
and three lines of chemo therapy on average. Second line chemotherapy regimens 
varied. Capecitabine was the most common therapy (mono and combination) in 
all countries ranging from 36% (UK) to 40% (Germany). 2nd and 3rdmost common 
therapies were vinorelbine (23%-26%) and paclitaxel (20%-23%) in Germany, Italy 
and Spain vs. docetaxel (18%-34%) and paclitaxel (11%-19%) in UK and France. 
In third line, the most commonly used agents were capecitabine (16%-44%) and 
vinorelbine (18%-26%). Eribulin was used in second line (3%-6%) and third line (11%-
19%) in all countries except for Spain. ConClusions: Capecitabine is the most 
utilized chemotherapeutic agent in the second and third lines chemotherapy in 
Western Europe for HER2-negative patients. A variety of other regimens, primarily 
monotherapies, may also be used in later lines, including vinorelbine, gemcitabine, 
eribulin, and docetaxel.
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objeCtives: Several studies suggest that diabetes carries an increased risk for 
a number of different cancer types. The aim of this study was to investigate the 
incidence of 14 different cancer types in the diabetic and non-diabetic popula-
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(lowest vs highest; HR 1.12, 95%CI 1.07-1.16), grade (high vs low, HR 1.72, 95%CI 
1.63-1.82), tumour size (2-5 cm vs 1-2 cm; HR 1.46, 95%CI 1.40-1.51), and a higher 
number of positive lymph nodes (1-3 vs 0; HR 1.40, 95%CI 1.34-1.46 and > 10 vs 0; HR 
3.19, 95%CI 3.00-3.39) influenced death, all to a larger extent than surgical volume 
did. ConClusions: In the Netherlands, surgical hospital volume influences 10-year 
overall survival only marginally, and far less than patient and tumour characteris-
tics. No difference in survival was revealed for invasive non-metastatic breast cancer 
patients in hospitals with 75-99 operations per year compared with hospitals with 
over 200 operations per year.
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objeCtives: For patients with relapsed or refractory (R/R) mantle cell lymphoma 
(MCL), prognosis is poor, with a median survival of one to two years, and treat-
ment options are very limited. In a recent phase II trial (PCYCY-1104), Ibrutinib 
(Imbruvica™), a first-in-class oral once a day covalent Bruton’s tyrosine kinase 
inhibitor, was associated with a median progression-free survival (PFS) of 13.9 
months. After a median follow-up of 15.3 months, 63% of patients were alive. 
The aim of the current study was to evaluate the projected life years (LYs) and 
quality-adjusted LYs (QALYs) associated with ibrutinib and other treatments for 
R/R MCL. Methods: Patients with R/R MCL were simulated to receive treatment 
in a health state, survival partition model. Patients received ibrutinib, bendamus-
tine and rituximab (BR), fludarabine, mitoxantrone, and cyclophosphamide (FMC), 
temsirolimus, or other comparators until death or until progression of disease, 
at which point they were modeled to receive a subsequent line of treatment or 
best supportive care. Clinical inputs for ibrutinib were informed by PCYC-1104 
trial data; OS was extrapolated to estimate survival outcomes. Clinical inputs for 
comparators were informed by published sources identified through a systematic 
literature review. Utility values were informed by published studies. Outcomes 
were discounted by 3.5%. Results: Treatment with ibrutinib resulted in better 
health outcomes, incrementally increasing overall LYs by 0.92, 0.86, and 0.92 and 
PFS LYs by 0.87, 0.87, and 0.87 compared to BR, FMC, and temsirolimus, respec-
tively. Ibrutinib was associated with 0.71, 0.70, and 0.72 overall incremental QALYs 
compared to BR, FMC, and temsirolimus, respectively. ConClusions: Compared 
with other therapies, Ibrutinib yielded an average incremental benefit of 0.90 LYs 
for R/R MCL patients, largely driven by the significant incremental improvement 
in duration of PFS. Currently a phase III trial is ongoing, the data from which will 
be used to validate the model.
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objeCtives: This study was aimed at evaluating the overall survival (OS) gains 
associated with HER-2 directed therapies in patients with metastatic breast 
cancer. Methods: A bibliographic search was conducted in the MEDLINE (PubMed) 
and in the Cochrane Central Register of Controlled Trials databases, from their 
inception through March, 2014. Only phase III clinical trials (RCTs) including 
HER2-positive metastatic breast cancer patients have been included in this review, 
irrespective of the treatment administered (i.e., chemotherapy and/or hormone 
therapy, chemotherapy and/or hormone therapy plus HER2-targeted therapy). OS 
was defined as time from randomisation until the occurrence of death from any 
cause. Studies have been grouped according to the line of treatment, i.e. first-line 
or second-line or beyond. Results: Seventeen RCTs were eligible for inclusion, of 
which 12 assessed therapies targeting metastatic breast cancer HER2+ in the first 
line setting. OS improved from 20.3 months in the first RCT (standard chemotherapy; 
Slamon et al, 2001) evaluating HER-2 targeting therapies to 48 months (estimated 
median OS) in the study of Swain and colleagues (2013), with triple combination 
of pertuzumab, trastuzumab and docetaxel. Four studies evaluated OS of HER-2 
targeting therapies in second-line setting of metastatic breast cancer. The OS in 
second-line setting improved from 15.3 months (capecitabine; Cameron et al, 2008) 
to 30.7 months (trastuzumab emtancine; Verma et al, 2012). In the third-line setting, 
the association of lapatinib + trastuzumab has demonstrated to improve OS in 4.5 
months compared with lapatinib alone (14 months vs 9.5 months; Blackwell et al, 
2012). ConClusions: The HER-2 directed therapies had an undeniable benefic 
impact in the overall survival of patients with HER-2 positive metastatic breast 
cancer. Triple combination of docetaxel, pertuzumab and trastuzumab is associated 
with a survival extent of more than 3.5 years, compared with a life expectancy of 
1,5 years achieved 13 years ago.
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objeCtives: Treatment options for chronic lymphocytic leukemia (CLL) who 
received prior therapy are limited; no standard of care exists. In a recent phase 
III clinical trial (PCYC-1112), ibrutinib, an oral, once-a-day, first-in-class covalent 
Bruton’s tyrosine kinase inhibitor, was associated with improved progression-free 
survival (PFS, HR= 0.215) and overall survival (OS, HR= 0.387) compared with ofa-
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objeCtives: The association between the disease-free interval (DFI) and survival 
after a locoregional recurrence (LRR) or second primary (SP) breast cancer remains 
uncertain. The objective of this study is to clarify this association to obtain more 
information on expected prognosis. Methods: Women first diagnosed with early 
breast cancer between 2003-2006 were selected from the Netherlands Cancer 
Registry. LRRs and SP tumours within five years of first diagnosis were examined. 
The five-year period was subsequently divided into three equal intervals. Prognostic 
significance of the DFI on survival after a LRR or SP tumour was determined using 
Kaplan-Meier estimates and multivariable Cox regression analysis. Follow-up was 
complete until January 1,2013. Results: A total of 36,255 women was included in 
the analysis. LRRs or SP tumours were diagnosed in 1,646 (4.5%) patients: 55% devel-
oped a LRR and 45% SP breast cancer. Longer DFI was strongly and independently 
related to an improved survival after a LRR (long versus short: HR 0.63, 95% CI 0.46-
0.86; medium versus short HR 0.80, 95% CI 0.64-1.00; P for trend 0.01). Other factors 
related to improved survival after LRR were younger age (< 70 years) and surgical 
removal of the recurrence. No significant association was found between DFI and 
survival after SP tumours. ConClusions: This is the first study to explore the asso-
ciation between the DFI and survival after recurrence in a nationwide population-
based cancer registry. The DFI before a LRR is an independent prognostic factor for 
survival, with a longer DFI predicting better prognosis.
PCN36
loNG terM survival of PatieNts with various luNG CaNCer histoloGy 
iN seer betweeN 2004-2011
Schmaus K1, Benedict A2
1Evidera, San Francisco, CA, USA, 2Evidera, Budapest, Hungary
objeCtives: Overall survival (OS) data from clinical trials in oncology are often 
incomplete, thus modelling over the lifetime horizon requires long term extrapola-
tion and it is a critical input to cost-effectiveness studies. Data from the Surveillance, 
Epidemiology, and End Results (SEER) program may provide good validation on the 
long term OS. The objective was to examine the parametric functions that best 
fit data in lung cancer (LC) of various histologies in SEER. Methods: SEER data 
(2004-2011) were analyzed for patients diagnosed with stage IV small cell, large cell, 
squamous cell carcinoma and adenocarcinoma of the lung with complete follow-
up. Mean age was 68.03 (sd 11.67) and 55.5% were males, with varying baseline age 
and gender distribution by histology. Treatment status could not be established. 
Parametric models for OS were fitted using exponential, Gompertz, loglogistic, log-
normal, and Weibull distributions. Models were fitted with and without covariates. 
Fits were inspected and compared graphically using survival and quantile-quantile 
plots, and statistically using the Akaike Information Criterion (AIC). Modelled mean 
life expectancy results were compared to the restricted mean life expectancy of 
the Kaplan-Meier estimator. Results: The lognormal distribution was found to 
have the best fit within the SEER population, both with and without covariates 
indicating that a small proportion of patients survive for a long time despite the 
poor general prognosis of any type of LC. Loglogistic and gamma distributions were 
2nd and 3rd best, followed by Weibull, Gompertz and exponential, for all histolo-
gies. The last three fitted the data poorly, and underestimated mean life expec-
tancy. ConClusions: Only small proportions of LC patients are alive at 5-8 years, 
nevertheless the mean OS estimates are impacted by the choice of survival function. 
The lognormal distribution fit best across all histologies indicating a higher propo-
tion of patients alive than estimated with Weibull models.
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objeCtives: For low-volume tumours, high surgical hospital volume is associated 
with better survival. For high volume tumours like breast cancer this association 
is unclear. The aim of this study is to determine to what extent the yearly surgi-
cal hospital breast cancer volume is associated with overall survival. Methods: 
All patients, diagnosed with primary invasive non-metastatic breast cancer in the 
period 2001-2005, were selected from the Netherlands Cancer Registry. Hospitals 
were grouped by their annual volume of surgery for invasive breast cancer. Cox 
proportional hazard models were used including patient and tumour characteris-
tics as covariates. Follow-up was completed until the 1thof February 2013. Primary 
endpoint was 10-year overall survival rate. Results: In total 58,982 patients with 
invasive non-metastatic breast cancer were diagnosed during the period 2001-2005. 
Hospitals were grouped by their (mean) annually surgical volume: < 75 (n= 19), 75-99 
(n= 30), 100-149 (n= 29), 150-199 (n= 9) and ≥ 200 (n= 14). The 10-year observed survival 
rates were 77%, 81%, 80%, 82% and 82%, respectively. After case-mix adjustment 
patients in low volume hospitals had a HR of 1.08 (< 75 vs ≥ 200; 95%CI 1.02-1.14). 
Age at diagnosis (continuous, HR 1.05, 95%CI 1.05-1.05), socioeconomic status 
